Skip navigation
Watchlist Sponsored By :


Current DateTime: 12:36:31 15 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 12:36:31 15 Nov 2009
LinksList Documentid: 33793611
  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?

  • Think You Understand Markets?

      We've selected some questions from the Financial Industry Regulatory Authority's test of investor knowledge. See how you do ...


Current DateTime: 12:36:31 15 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
GlaxoSmithKline Posts 16% Rise in Full-Year Profit
By: CNBC.com | 08 Feb 2007 | 08:08 AM ET
Text Size

GlaxoSmithKline, [GSK  Loading...      ()   ] Europe's biggest drug maker, reported a 16% rise in annual profit Thursday, in line with expectations of analysts polled by Reuters. But the company said 2007 growth would slow as it awaits pipeline renewal.

Fourth-quarter profit before tax was $2.2 billion, up from $2.08 billion in the same three months ending December in 2005.

Sales in the fourth-quarter rose to $7.79 billion from $7.66 billion, helped by strong U.S. demand.

For the coming year, GSK forecast EPS growth in constant exchange rate terms of between 8% to 10% -- better than the low single-digit level some analysts had expected.

GSK said that it plans launch 5 major new pharmaceutical products in 2007:Tykerb, which is a breast cancer drug; Allermist/Avamys, a allergic rhinitis treatment; Coreg, for treating heart conditions and Trexima for migraines. The company also, said that it expects to file for U.S. approval for cervical cancer vaccine Cervarix in April.

Competition from generic drug makers will increase for major pharmaceuticals in 2007, and GSK is no exception with both its anti-nausea drug Zofran and anti-depressant Wellbutrin XL set to face new rivals.

The company's shares rose more than 1% in London in reaction to the results.

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
  • Brian L. Roberts
  • For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
  • Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
  • The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
  • Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
  • A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
ADD COMMENTS
Remaining characters


Current DateTime: 01:04:47 14 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:04:47 14 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:04:47 14 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:04:04 14 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters